APA (7th ed.) Citation

H, Z., AD, W., LM, R., & JL, L. (2026). Reply to Improda, N.; Ballarin, G. Body Composition in Paediatric GLP-1 Receptor Agonist Therapy. Comment on "Zaitoon et al. Beyond Weight Loss: Optimizing GLP-1 Receptor Agonist Use in Children. Children 2025, 12, 1427". Children (Basel, Switzerland), 13(5), . https://doi.org/10.3390/children13050608

Chicago Style (17th ed.) Citation

H, Zaitoon, Wauters AD, Rodriguez LM, and Lynch JL. "Reply to Improda, N.; Ballarin, G. Body Composition in Paediatric GLP-1 Receptor Agonist Therapy. Comment on "Zaitoon Et Al. Beyond Weight Loss: Optimizing GLP-1 Receptor Agonist Use in Children. Children 2025, 12, 1427"." Children (Basel, Switzerland) 13, no. 5 (2026). https://doi.org/10.3390/children13050608.

MLA (9th ed.) Citation

H, Zaitoon, et al. "Reply to Improda, N.; Ballarin, G. Body Composition in Paediatric GLP-1 Receptor Agonist Therapy. Comment on "Zaitoon Et Al. Beyond Weight Loss: Optimizing GLP-1 Receptor Agonist Use in Children. Children 2025, 12, 1427"." Children (Basel, Switzerland), vol. 13, no. 5, 2026, https://doi.org/10.3390/children13050608.